Abstract
Topic: Mutual association and connection study between the obesity, visceral obesity, insulin desensitation (with the conesquential hyperinsulinemia), type 2 diabetes, dyslipoproteinemia and anthropometric characteristics of the patients with the metabolic syndrom are the subject of many epidemiological studies. However, it is noticed that there are certain disagreements and contradictions in defining the anthropometric and metabolic risk factors for the occurance of the cardiovascular, cerebrovascular and other vascular diseases, especially in population of the obese patients with type 2 diabetes. Topic position in medical public: Theoretically, metformin achieves a good glicoregulation preciselyinthe visceral obese patients. This is explained by a higher glucometabolic activity of the visceral adipose tissue in regard to the subcutenaus tissue. Further action: More efficient reduction of the visceral adipose tissue inpatients with achieved better glucoregulation, under the affection of the metformin is a result of its complex effect mechanism. Metformin plays a significant role in the reduction of the cardiovascular risk that comes from a higher visceral obesity, parallel to the achievement of the good glicoregulation in obese, type 2 diabetes patients.
Highlights
Metformin increases insulin binding to its receptors by increasing the phosphorylation and the tyrosine kinase activity on the insulin receptors in vivo, so this could lead to a reduction in plasma glucose, which could not be reproduced in vitro [33]
We showed that in obese type 2 diabetes patients, metformin reduces unproductive fast insulin secretion and increases its productive postprandial secretion [38]
Our previous results indicate that the three-month application of metformin in obese patients with type 2 diabetes, and patients with impaired glucose tolerance more often led to normalization of HbA1c levels in patients with pretherapy level of HbA1c < 8% compared to patients with HbA1c ≥ 8% [41,42]
Summary
Topic: Mutual association and connection study between the obesity, visceral obesity, insulin desensitation (with the conesquential hyperinsulinemia), type 2 diabetes, dyslipoproteinemia and anthropometric characteristics of the patients with the metabolic syndrom are the subject of many epidemiological studies. Topic position in medical public: Theoretically, metformin achieves a good glicoregulation preciselyinthe visceral obese patients. This is explained by a higher glucometabolic activity of the visceral adipose tissue in regard to the subcutenaus tissue. Metformin plays a significant role in the reduction of the cardiovascular risk that comes from a higher visceral obesity, parallel to the achievement of the good glicoregulation in obese, type 2 diabetes patients. As well as for the development of the mentioned metabolic deseases, answering how or in which way does it come to the increasement of the body adipose tissue has a great clinical significance. There are two ways of increasing body adipose tissue in obesity – proliferation or adipose hypertrophy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
